|
30.01.2023 08:00:03
|
Unaudited NAV for December 2022
|
Arix Bioscience PLC (ARIX)
Arix Bioscience plc
Unaudited NAV for December 2022
LONDON, 30 January 2023: Arix Bioscience plc (Arix or the Company) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (NAV) of the Company for the date ended 31 December 2022 as follows:
[ENDS]
Enquiries For more information on Arix, please contact:
Arix Bioscience plc +44 (0)20 7290 1050 ir@arixbioscience.com
Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446 arix@powerscourt-group.com
About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
|
||||||||||||||||||
| ISIN: | GB00BD045071 |
| Category Code: | NAV |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 219090 |
| EQS News ID: | 1545893 |
| End of Announcement | EQS News Service |
|
|
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arix Bioscience PLC Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Arix Bioscience PLC Registered Shsmehr Analysen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.